Using a noninvasive test to measure kidney health in lupus nephritis patients
Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
This study is testing a simple, noninvasive way to measure kidney health in adults with lupus nephritis to see if it can help track their disease activity.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 55 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06631404 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the Renal Arterial Resistive Index (RRI) as a noninvasive biomarker for assessing disease activity in patients with lupus nephritis. The study will involve adult patients diagnosed with systemic lupus erythematosus (SLE) who meet specific classification criteria, alongside matched controls. Participants will undergo renal Doppler assessments to measure RRI, which may provide insights into the severity and progression of their condition. The goal is to identify a reliable indicator that can help in monitoring lupus nephritis without invasive procedures.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a diagnosis of systemic lupus erythematosus who meet the SLICC classification criteria.
Not a fit: Patients with other autoimmune diseases, diabetes, hypertension, or any significant renal or cardiovascular conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new, noninvasive method for monitoring disease activity in lupus nephritis patients, potentially leading to better management of their condition.
How similar studies have performed: While the use of RRI as a biomarker in lupus nephritis is being explored, this approach is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged ≥18 years. * SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls. * Patients cooperative and can answer questions. * Patients who are able and willing to give written informed consent. Exclusion Criteria: * • Individuals with other autoimmune diseases. * Diabetes. * Hypertension. * Heart failure. * Hepatic diseases. * Chronic renal failure. * Renal artery stenosis. * Renal vein thrombosis. * Intrarenal arteriovenous fistula. * Obstructive nephropathy. * Urinary tract obstruction that could affect RI of intra renal arteries. * Un cooperative patients. * Patients not able and willing to give written informed consent.
Where this trial is running
Sohag
- Sohag university Hospital — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: Doaa R Abdelkarim, resident
- Email: doaa_rabea_post@med.sohag.edu.eg
- Phone: 01027673294
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.